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Prediction of peritoneal relapse is extremely important for gastric cancer patients after curative surgery. The present study
prospectively validates the prognostic ability of quantifying carcinoembryonic antigen (CEA) mRNA in peritoneal washes by real-time
reverse transcriptase–polymerase chain reaction. Based on a retrospective study of 197 curatively resected gastric cancer patients
(training set), we determined a cutoff value of CEA mRNA using receiver-operating characteristic curve. We used this cutoff value to
validate the risk of peritoneal recurrence in a new cohort of 86 gastric cancer patients (validation set) between July 2000 and
December 2002 in a prospective study. During the median 30 months of postoperative surveillance, 20 of the 86 patients died, and
13 of the 20 developed peritoneal metastases. Peritoneal recurrence-free survival as well as overall survival was significantly worse in
patients with positive CEA mRNA (Po0.0001). Multivariate analysis with the Cox proportional hazards model showed that positive
CEA mRNA was a significant independent risk factor with both survival (P¼0.0130) and peritoneal recurrence-free survival
(P¼0.0006) as end points. These results indicate that quantitation of CEA mRNA in peritoneal washes is a reliable prognostic
indicator of peritoneal recurrence in the clinical setting.
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Although the survival of patients with gastric cancer has improved
due to the development of new diagnostic tools for early detection
and the nationwide practice of mass screening, gastric carcinoma
remains a leading cause of cancer death in Japan as well as in
other countries. Peritoneal dissemination, the most frequent type
of recurrence in patients with gastric cancer, is considered to arise
from free cancer cells in the peritoneal cavity exfoliated from the
serosal surface of the stomach penetrated by the primary tumour.
Peritoneal washes have been cytologically examined at laparotomy
as an international gold standard to detect such tumour cells and
to evaluate the risk of peritoneal recurrence (Boku et al, 1990;
Bonenkamp et al, 1996; Bando et al, 1999; Hayes et al, 1999;
Kodera et al, 1999). The results of this procedure are recognised as
an important prognostic determinant (Bonenkamp et al, 1996;
Hayes et al, 1999); however, conventional Papanicolaou staining
lacks sensitivity and some patients whose washes were cytologi-
cally negative develop recurrent disease in the peritoneal cavity
after surgery (Abe et al, 1995). Although several investigators have
reported that immunohistochemistry with antibody panels can be
an aid to conventional cytology (Juhl et al, 1994; Benevolo et al,
1998), sensitivity still needs to be increased. We therefore applied
the reverse transcriptase–polymerase chain reaction (RT–PCR) to
detect micrometastases in the peritoneal cavity, using carcino-
embryonic antigen (CEA) as the target gene (Nakanishi et al, 1997;
Kodera et al, 1998). We then applied real-time RT–PCR to
quantify free cancer cells in peritoneal washes (Nakanishi et al,
2000) and declared the prognostic significance of intra-abdominal
CEA mRNA levels (Kodera et al, 2002). Since this report, many
investigators have concurred that CEA mRNA levels represent an
accurate retrospective determination of the risk of peritoneal
recurrence in patients with gastric cancer (Yonemura et al, 2001;
Fujii et al, 2002; Marutsuka et al, 2003; Tokuda et al, 2003; Ueno
et al, 2003; Oyama et al, 2004). In breast cancer, the front lines of
micrometastasis research, several prospective studies have demon-
strated the prognostic significance of the detection of micro-
metastasis in the sentinel lymph node or circulating tumour cells
in the blood in node-negative cancer patients (Gillanders et al,
2004; Jotsuka et al, 2004). However, such prospective quantitative
studies of micrometastasis in patients with gastric cancer have not
been reported.
Based on a cutoff value predetermined from retrospective
studies between 1995 and 2000, we validated the ability of
quantitative CEA mRNA detection in peritoneal washes to predict
peritoneal recurrence in a prospective study between 2000 and
2004. We confirmed that levels of CEA mRNA can predict
peritoneal recurrence in patients with gastric cancer who under-
went curative resection and discuss its therapeutic application for
selecting patients who might benefit from chemotherapy in the
clinical setting.
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sMATERIALS AND METHODS
Study design
The study consisted of sequential training and validation subsets.
The training set was a retrospective study of 197 patients with
gastric cancer who underwent curative surgery at Aichi Cancer
Center Hospital between April 1995 and March 1999. During this
period, CEA mRNA expression was examined in peritoneal washes
from 256 patients. Among these, 49 patients with liver and/or
peritoneal metastases at laparotomy, nine with macroscopically
residual disease and one with another active malignancy were
excluded from this study. The cutoff value of CEA mRNA was
determined from this study by analysing receiver-operating
characteristic (ROC) curve based on CEA mRNA values and
clinical follow-up data until April 2000 with a median follow-up
period of 38 months. The validation set was a prospective cohort
study to validate the ability of quantitative CEA mRNA detection
in peritoneal washes to predict peritoneal relapse based on the
predetermined cutoff value. The eligibility criteria consisted of (1)
histologically proven gastric cancer, (2) cancer resected without
residual disease, (3) absent peritoneal metastases at laparotomy,
(4) absent liver metastases at laparotomy, (5) no other active
malignancy and (6) provision of written informed consent. Eighty-
six patients who underwent potentially curative resection were
enrolled between July 2000 and December 2002. This study was
approved by the institutional review board of our hospital.
Furthermore, the study was also approved by the Ministry of
Health, Labor and Warfare of Japan as a highly advanced medical
technology specialising in the genetic diagnosis of solid tumours.
Peritoneal wash specimens
Aliquots of 100–200ml of saline were introduced into the Douglas
cavity and left subphrenic space at the beginning of each operation
and aspirated soon after gentle stirring. One-half of each wash was
sent to routine cytopathology with conventional Papanicolaou
staining and the other half of the wash was used to measure CEA
mRNA levels. Intact cells collected from the washes by centrifuga-
tion at 1800r.p.m. for 5min were rinsed with phosphate-buffered
saline (PBS), dissolved in ISOGEN-LS RNA extraction buffer
(Nippon Gene, Tokyo, Japan) and stored at  801C.
Real-time quantitative reverse transcriptase–polymerase
chain reaction
Frozen samples in ISOGEN-LS were thawed and total RNA was
extracted using guanidinium isothiocyanate–phenol–chloroform.
cDNA was synthesised from total RNA using SuperScript II RNase
H
  reverse transcriptase (Invitrogen, Carlsbad, CA, USA) accor-
ding to the manufacturer’s instruction. The resultant first-strand
cDNA was stored at  801C until analysis. Single-step real-time
RT–PCR for CEA mRNA was performed using CEA-specific
oligonucleotide primers and two fluorescent hybridisation probes
on the LightCycler instrument (Roche Diagnostics, Mannheim,
Germany) as described previously (Nakanishi et al, 2000; Kodera
et al, 2002). To quantify and prove the integrity of the isolated
RNA, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
also analysed by real-time RT–PCR using the appropriate primers
and hybridisation probes. All primers and probes were synthesised
and purified by reverse-phase HPLC at Nihon Gene Research
Laboratories (Sendai, Japan).
Six external CEA mRNA standards were prepared by 10-fold
serial dilution (1–10
5 cells) of cDNA equivalent to 1 10
6 COLM-2
(a colon cancer cell line that expresses large amounts of CEA) cells
spiked into 1 10
7 peripheral blood leucocytes. Each run consisted
of six external standards, a negative control without a template and
patient samples with unknown mRNA concentrations. The amount
of mRNA in each sample was then automatically measured by
reference to the standard curve constructed each time on the
LightCycler software. The higher CEA mRNA value of two washes
(Douglas cavity and subphrenic space) from each patient was
selected. If at least one CEA mRNA value from the two washes
was above the cutoff value, the patient was considered positive for
CEA mRNA.
Data management
The CEA mRNA levels in peritoneal washes were measured
by investigators who were blinded to the clinical information of
the patients. The results were reported as positive or negative
judgments together with relative CEA mRNA values within 2 weeks
of sampling. For research purposes, all of the CEA mRNA and
clinical data including follow-up information indexed by a unique
subject number were given to the chief investigator for further
analysis. Tumours were staged according to the TNM classification
(5th edition, 1997) and the categories were determined from
pathological findings based on surgically resected specimens.
Postoperative surveillance of patients
Postoperative surveillance proceeded according to the prospective
follow-up protocol for individual patients until September 2004
with a median follow-up period of 30 months (range, 21–50
months). The protocol consisted of interim history, physical
examination, haematology and blood chemistry panels including
tests for CEA and CA19-9, performed every 3 months for the first
postoperative year and every 6 months thereafter. The patients
were examined by either abdominal ultrasonography or computed
tomography every 6 months. Peritoneal recurrence evident
according to clinical symptoms, digital examination and physical
as well as radiological findings of bowel obstruction and ascites
was confirmed by paracentesis, laparotomy and autopsy per-
formed at the discretion of the surgeon.
Statistical analysis
Receiver-operating characteristic (ROC) curve determined the
cutoff value of CEA mRNA as reported (Zweig and Campbell, 1993;
Kodera et al, 2002). Briefly, ROC curve was constructed by plotting
all possible sensitivity/1 specificity pairs resulting from conti-
nuously elevating the cutoff values over the range from 0 to 40000.
Sensitivity in this context was defined as a positive rate of CEA
mRNA determined during postoperative surveillance, in peritoneal
washes from patients with relapses in the form of peritoneal
carcinomatosis. Specificity was defined as the negative rate of CEA
mRNA among patients without signs of peritoneal recurrence
during postoperative surveillance. The CEA mRNA values among
each pT category were compared using the Kruskal–Wallis test.
Survival was analysed by Kaplan–Meier curves with death and
a clinical diagnosis of peritoneal recurrence as end points. Cancer
deaths resulting from other types of metastasis in the absence of
clinical signs of peritoneal recurrence were treated as censored.
Multivariate analysis using the Cox regression hazards model
identified independent prognostic factors. Tumour size, histologi-
cal type, serosal invasion and lymph node metastasis were selected
as covariates, along with CEA mRNA status.
RESULTS
Clinicopathological characteristics of patients in training
and validation sets
Table 1 summarises the characteristics of the patients with gastric
cancer who were enrolled in the training (retrospective study) and
validation (prospective study) sets. All of the patients underwent
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scurative surgery with R0 resection, but the variables considerably
differed between the training and validation sets. The validation set
contained significantly more patients with advanced disease than
the training set in terms of T (P¼0.0003) and N (Po0.0001)
categories. The incidence of patients with advanced gastric cancer
(T2–T4) in the training and validation sets was 53.8 and 77.9%,
respectively. The incidence of node-positive patients in the
training and validation sets was 46.2 and 73.3%, respectively. In
contrast, the incidence of patients with positive peritoneal wash
cytology was much lower in the validation set (1.2%) than in the
training set (9.1%).
The CEA mRNA level in the peritoneal washes
Real-time RT–PCR using the LightCycler allowed quantitative and
sensitive detection of CEA mRNA from patient samples ranging
from 1 to 1 10
5 colon carcinoma cells expressing CEA (COLM-2).
Carcinoembryonic antigen mRNA was undetectable in peritoneal
washes from eight patients with benign disease and in peripheral
blood from 15 healthy volunteers as reported (Nakanishi et al,
2000). We also confirmed the integrity of extracted RNA with the
quantitation of internal control GAPDH mRNA and omitted two
of the 256 samples in which GAPDH mRNA was undetectable
in the training set (data not shown).
The cutoff value of the CEA mRNA was determined by reference
to the ROC curve obtained from 197 patients in the training set.
We selected 0.1 as the CEA mRNA cutoff value to allow maximal
sensitivity (89.7%) with a minimal false-positive fraction (17.3%).
Figure 1 shows the CEA mRNA expression levels of patients with
gastric cancer in the training and validation sets according to the
depth of tumour invasion (T category). The CEA mRNA values
correlated with the depth of tumour invasion in both training and
validation sets (Po0.0001) (Figure 1). In the training set, average
CEA mRNA values in the peritoneal washes were 0.35, 23, 1119 and
164 for pT1, pT2, pT3 and pT4 tumours, respectively. The positive
rates for CEA mRNA were 9.9% (nine out of 91), 26.3% (15 out of
57), 60.0% (24 out of 40) and 77.8% (seven out of nine) in T1, T2,
T3 and T4 patients, respectively. In the validation set, average CEA
mRNA values were 0, 0.31, 1035 and 71 in patients with T1, T2, T3
and T4 tumours, respectively. The positive rates for CEA mRNA
were 0% (0 out of 19), 7.1% (two out of 28), 45.7% (16 out of 35)
and 50.0% (two out of four) in T1, T2, T3 and T4 patients,
respectively.
Relationship between survival and CEA mRNA expression
In the training set, overall survival as well as peritoneal recurrence-
free survival among the 197 patients was significantly worse for
those with positive CEA mRNA (Po0.0001) (Figure 2A and B).
A positive rate of CEA mRNA in peritoneal washes from patients
with relapses in the form of peritoneal carcinomatosis during
postoperative surveillance was 89.7%. Using the cutoff value
determined by the training set, we estimated the survival of 86
patients in the validation set. During follow-up until September
2004, 20 patients died from peritoneal (n¼13), lymph node
(n¼7), bone (n¼2) and liver (n¼2) metastases. Twenty of 86
patients (23.3%) were positive for CEA mRNA expression and 12
of these 20 (60.0%) patients died from cancer, but only eight of the
remaining 66 (12.1%) who were CEA mRNA-negative died. Overall
survival in the 86 patients was significantly worse for those with
positive CEA mRNA (Po0.0001) (Figure 2C). Among the 86
patients, 13 (15.1%) developed peritoneal metastases. Eleven of the
20 CEA mRNA-positive patients (55.0%) developed peritoneal
recurrence, but only two of the remaining 66 patients (3.0%) who
were negative for CEA mRNA developed peritoneal disease.
Peritoneal recurrence-free survival was also significantly worse in
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Figure 1 Relative CEA mRNA values of peritoneal washes from gastric
cancer patients measured by real-time RT–PCR according to the depth of
cancer invasion (pT category) in the training set (A) and the validation set
(B). The CEA mRNA values correlate statistically with depth of invasion in
both sets (Po0.0001). Bars indicate mean CEA mRNA values.
Table 1 Patients characteristics of training set and validation set
Variate Training set Validation set P-value
Tumour size
p5cm 107 (54.3%) 39 (45.3%) 0.1961
45cm 90 (45.7%) 47 (54.7%)
Histological type
Differentiated 66 (33.5%) 28 (32.6%) 0.8767
Undifferentiated 131 (66.5%) 58 (67.4%)
T stage
t1 91 (46.2%) 19 (22.1%) 0.0003
t2 57 (28.9%) 28 (32.6%)
t3 40 (20.3%) 35 (40.7%)
t4 9 (4.6%) 4 (4.7%)
Lymph node metastasis
Negative 106 (53.8%) 23 (26.7%) o0.0001
Positive 91 (46.2%) 63 (73.3%)
Peritoneal wash cytology
Class I 100 (50.8%) 78 (90.7%) o0.0001
Class II 74 (37.6%) 3 (3.5%)
Class III 5 (2.5%) 4 (4.7%)
Class IV 1 (0.5%) 0 (0.0%)
Class V 17 (8.6%) 1 (1.2%)
CEA mRNA status in peritoneal wash
Negative 142 (72.1%) 66 (76.7%) 0.4657
Positive 55 (27.9%) 20 (23.3%)
Operative type
Distal gastrectomy 133 (67.5%) 45 (52.3%) 0.0635
Proximal gastrectomy 12 (6.1%) 6 (6.9%)
Total gastrectomy 51 (25.9%) 33 (38.4%)
Pancreaticoduodenectomy 1 (0.5%) 2 (2.3%)
Adjuvant chemotherapy
Yes 41 (20.8%) 11 (12.8%) 0.1334
No 156 (79.2%) 75 (87.2%)
CEA¼carcinoembryonic antigen.
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spatients with positive CEA mRNA (Po0.0001) (Figure 2D). A
positive rate of CEA mRNA in peritoneal washes from patients
with relapses in the form of peritoneal carcinomatosis during
postoperative surveillance was 84.6%.
Multivariate analysis of prognostic factors in the
prospective study
A Cox regression analysis with overall survival as the end point
identified independent prognostic factors among covariates
including CEA mRNA status, tumour size, histological type,
serosal invasion and lymph node metastasis. Carcinoembryonic
antigen mRNA along with serosal invasion was an independent
prognostic factor for the 86 patients with gastric carcinoma who
underwent curative resection (P¼0.0130) (Table 2). Multivariate
analysis with peritoneal recurrence-free survival as the end point
revealed only CEA mRNA as an independent prognostic factor
(P¼0.0006) (Table 3).
DISCUSSION
The present prospective study confirmed that the prognosis was
significantly worse for patients with positive CEA mRNA than
negative. Furthermore, multivariate analysis identified positive
CEA mRNA as an independent prognostic factor. Since we
described the quantitative detection of free tumour cells in
peritoneal washes (Nakanishi et al, 2000) and its prognostic
significance for gastric cancer patients (Kodera et al, 2002),
many investigators have reported the usefulness of quantitative
CEA mRNA detection in retrospective risk assessments of
peritoneal recurrence (Nakanishi et al, 2004). To our knowledge,
the present study is the first prospective validation of quantitative
CEA mRNA detection in peritoneal washes as a reliable prognostic
indicator of peritoneal recurrence in the clinical setting for gastric
cancer patients.
Quantitative detection of CEA mRNA has been a matter of some
controversy, such as determination of the cutoff value and whether
or not to correct CEA mRNA values using an internal standard.
In our preliminary study as well as those of others (Oyama et al,
2004), the cutoff value was determined based on the meanþ2 s.d.
(standard deviation) of control samples derived from patients who
underwent surgery to treat benign diseases. Since CEA mRNA was
undetectable in the control samples in our system, the calculated
cutoff value would be zero, resulting in a high incidence of false-
positive results and low specificity. To avoid an arbitrary selection,
we performed ROC curve analyses to determine the optimal cutoff
A
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Figure 2 Survival curves of patients with positive and negative CEA mRNA in peritoneal washes in the training set (A, B) and validation set (C, D). Panels
(A, C) and (B, D) show the overall survival and peritoneal recurrence-free survival as end points, respectively. Patients positive and negative for CEA mRNA
in peritoneal washes significantly differed (Po0.0001, log-rank test) in both training and validation sets.
Table 2 Multivariate analysis of prognostic factors in the validation set
with overall survival as an end point
Variate Hazard ratio 95% confidence interval P-value
Tumour size
p5cm 1
45cm 0.54 0.19–1.51 0.2400
Histological type
Differentiated 1
Undifferentiated 1.97 0.78–4.97 0.1500
Serosal invasion
Negative 1
Positive 3.38 1.21–9.50 0.0210
Lymph node metastasis
Negative 1
Positive 0.78 0.37–1.65 0.5200
CEA mRNA status
Negative 1
Positive 1.79 1.13–2.85 0.0130
CEA¼carcinoembryonic antigen.
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recurrence risk. We selected a cutoff value of 0.1 to give maximal
sensitivity with a minimal false-positive fraction. Resultant
sensitivity and specificity were 89.7 and 82.7% in the training set
and 84.6 and 87.7% in the validation set, respectively. The cutoff
value of 0.1 was determined without reference to the data from
the validation set; nevertheless, the sensitivity and specificity
were almost equivalent between the two data sets, indicating the
reproducibility of the diagnostic ability of real-time CEA RT–PCR.
Whether to use a simple CEA mRNA value or the value corrected
with the internal control as a predictive indicator of peritoneal
recurrence is another controversial issue. Oyama et al (2004)
recommended using the CEA/GAPDH ratio from the viewpoint of
reliability. However, our previous comparison of the prognostic
values of CEA mRNA and the CEA/GAPDH ratio demonstrated
that the area under the ROC curves for CEA mRNA with or without
correction by GAPDH mRNA were essentially the same, indicating
that correction with reference to GAPDH mRNA may not be
strictly necessary (Kodera et al, 2002). We believe that the total
number of cancer cells represented by CEA mRNA rather than
the ratio of cancer/noncancer cells (CEA/GAPDH ratio) is a more
important hallmark for predicting peritoneal recurrence. We
therefore used simple, uncorrected CEA mRNA values for
subsequent analysis in the present study.
The validation set was characterised in the present study by
a greater number of advanced gastric cancer patients in terms
of T and N categories who were peritoneal wash cytology-negative,
reflecting the patient population that would benefit most from
the assessment of peritoneal recurrence risk by quantitative CEA
mRNA detection. Even in such a validation set, CEA mRNA proved
to be a significant independent prognostic factor by multivariate
analysis, with both overall survival and peritoneal recurrence-free
survival as the end points. In contrast to CEA mRNA in the
peritoneal washes, traditional markers such as depth of invasion
and lymph node status were, unexpectedly, not always prognos-
tically significant in the validation set. As for depth of tumour
invasion, multivariate analysis identified serosal invasion as an
independent prognostic factor when overall survival, but not
peritoneal recurrence-free survival, was adopted as the end point.
The lack of prognostic significance of serosal invasion in
peritoneal recurrence-free survival is probably because the depth
of tumour invasion correlates with not only peritoneal recurrence,
but also lymph node and/or haematogenous recurrence. These
findings suggest that CEA mRNA in the peritoneal washes is a
genuine prognostic factor for peritoneal recurrence, being more
reliable than serosal invasion (depth of invasion). On the other
hand, lymph node metastasis, which is generally known to be one
of the most important prognostic factors, was surely a significant
prognostic indicator for overall survival with both univariate and
multivariate analysis in the training set, whereas surprisingly,
lymph node status in the validation set was not a significant
prognostic factor even in the univariate analysis. We speculate that
this discrepancy between the training set and validation set is at
least in part due to the recent advances in chemotherapy for gastric
cancer. New-generation agents such as irinotecan, docetaxel,
paclitaxel and S-1 (oral DPD inhibitory fluoropyrimidine) have
been developed and used for gastric cancer patients with
promising antitumour effects (Futatsuki et al, 1994; Sakata et al,
1998; Koizumi et al, 2000; Yamada et al, 2001; Bang et al, 2002). In
fact, S-1 achieved the highest response rate (48%) among these
agents, especially for the distant lymph nodes (Sakata et al, 1998).
Therefore, S-1 was used in more than 80% of patients with
recurrence in our validation set, and 2-year survival rate for node-
positive patients was improved from 69.7% in the training set to
77.5% in the validation set, suggesting that lymph node metastasis
is more controllable than peritoneal metastasis by chemotherapy.
In addition, the shorter follow-up period of the validation set than
the training set might adversely affect estimation of the prognostic
ability of lymph node status.
It is somewhat puzzling that the positive rate of CEA mRNA in
the validation set (23.3%) was lower than that of the training set
(27.9%), although the validation set presented a higher incidence
of patients with ‘classical’ adverse prognostic factors such as
serosal invasion and/or lymph node metastases. Similarly, the
incidence of cytology-positive patients in the validation set was
much lower in the validation set (1.2%) than the training set
(8.6%). These discrepancies are considered to be mainly attribu-
table to two reasons. The first reason is our recent change in
therapeutic policy from resection to nonresection approach for
type IV (scirrhous type) gastric cancer with positive cytology
findings or laparoscopic evidence of peritoneal dissemination
(Kodera et al, 2001). In the same period as the validation set,
gastrectomy could be avoided in five scirrhous carcinoma patients
with positive cytology findings and another five patients with
peritoneal dissemination diagnosed for the first time by laparo-
scopy. These patients were not eligible for the present study and
therefore were excluded from the validation set, resulting in the
lower rate of CEA mRNA-positive and cytology-positive patients.
The second reason for the low incidence of positive CEA mRNA in
the validation set is our technical refinement of CEA mRNA
quantitation. The positive rate for CEA mRNA in T1-stage gastric
cancer patients is much lower in the validation set (0%) than in
the training set (9.9%), indicating a decrease in the false-positive
results in the validation set. In the present analysis, we did not add
peritoneal wash cytology as a covariate for multivariate analysis
because of the low incidence of cytology-positive patients (only
one patient) in the validation set. However, we examined and
confirmed that CEA mRNA was an independent prognostic factor
even in an analysis model including peritoneal wash cytology as a
covariate (data not shown).
Micrometastasis has recently been classified into ‘isolated
tumour cells (ITC)’, which are single tumour cells or a small cell
cluster that is no larger than 0.2mm at the greatest diameter,
and ‘micrometastases’, which are larger than 0.2mm according to
UICC (Sobin, 2003). The two classes should be separated because
ITC do not typically show morphological evidence of metastatic
activity such as penetration of a vascular or lymph sinus wall,
tumour cell growth and stromal reaction (Weaver, 2003; Cserni
et al, 2005). In fact, several investigators reported that ITC do not
become metastatic and will probably die or be eliminated by
immune surveillance (Holmgren et al, 1995). Quantitative CEA
Table 3 Multivariate analysis of prognostic factors in the validation set
with peritoneal recurrence-free survival as an end point
Variate Hazard ratio 95% confidence interval P-value
Tumour size
p5cm 1
45cm 0.32 0.06–1.68 0.1800
Histological type
Differentiated 1
Undifferentiated 2.64 0.55–12.70 0.2300
Serosal invasion
Negative 1
Positive 155.09 2.02E 10–1.19E+14 0.7200
Lymph node metastasis
Negative 1
Positive 0.65 0.21–1.97 0.4400
CEA mRNA status
Negative 1
Positive 3.99 1.80–8.84 0.0006
CEA¼carcinoembryonic antigen.
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sRT–PCR can detect such ITC and, therefore, we assume that the
specificity has an upper limitation of possibly 80–90% at maximal
incidence. The remaining 10–20% of the CEA mRNA-positive
patients without peritoneal recurrence might include those with
ITC and false positives.
Micrometastasis is clinically important not only as a prognostic
indicator as described above, but also as a potential therapeutic
target. A unique feature of micrometastases that distinguishes
them from macroscopic metastases is their high sensitivity to
anticancer drugs. Several experimental studies have demonstrated
a preferential therapeutic efficacy for micrometastases in the lung
(Kurebayashi et al, 1997) and peritoneum (Chaudhuri et al, 2001)
compared with macroscopic metastasis. Mice bearing gastric
cancer micrometastases in the peritoneal cavity survived longer
than those with macroscopic metastases after chemotherapy, and
some of them achieved pathological complete regression or were
cured (Nakanishi et al, 2003). Based on this chemosensitivity, we
proposed a new therapeutic strategy for protecting gastric cancer
patients from peritoneal recurrence after surgery. The strategy
consists of molecular diagnostic detection and subsequent
adjuvant chemotherapy targeted towards micrometastases. The
present study proved that quantitative CEA RT–PCR is a feasible
molecular diagnostic tool that can help to realise such a
therapeutic strategy.
In conclusion, we confirmed that quantitative real-time RT–
PCR is a powerful means of identifying subgroups of patients at
high risk for peritoneal relapse. The selection of high-risk patients
seems to be essential for treating gastric cancer patients with
individualised therapy. Exploratory phase II clinical trials of oral
5-FU derivatives for real-time RT–PCR-positive gastric cancer
patients are now ongoing in our institute.
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